Cancer Research AACR Membership  Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cascorbi, I.
Right arrow Articles by Brockmöller, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cascorbi, I.
Right arrow Articles by Brockmöller, J.
[Cancer Research 61, 5051-5056, July 1, 2001]
© 2001 American Association for Cancer Research


Epidemiology and Prevention

Association of NAT1 and NAT2 Polymorphisms to Urinary Bladder Cancer

Significantly Reduced Risk in Subjects with NAT1*101

Ingolf Cascorbi2, Ivar Roots and Jürgen Brockmöller

Institute of Clinical Pharmacology, University Medical Center Charité, Humboldt University, D-10098 Berlin [I. C., I. R., J. B.]; Institute of Pharmacology, Ernst Moritz Arndt University, D-17487 Greifswald [I. C.]; and Center of Pharmacology, Georg August University, D-37075 Göttingen [J. B.], Germany

The role of hereditary polymorphisms of the arylamine N-acetyltransferase 1 (NAT1) gene in the etiology of urinary bladder cancer is controversial. NAT1 is expressed in the urothelium and may O-acetylate hydroxyl amines, particularly in subjects with low NAT2 activity. Thus, NAT1 polymorphisms may affect the individual bladder cancer risk by interacting with environmental factors (smoking and occupational risks) and by interacting with the NAT2 gene. We studied the frequencies of the NAT1 haplotypes *3, *4, *10, *11, *14, *15, *17, and *22 in 425 German bladder cancer patients and 343 controls by PCR-RFLP. NAT1*10 allelic frequency was lower in bladder cancer patients (15.1%) compared with controls (20.4%; P = 0.012). Genotypes that included NAT1*10 were significantly less frequent among the cases (odds ratio adjusted for age, gender, and smoking, 0.65; 95% confidence interval, 0.46–0.91; P = 0.013). Two subtypes of NAT1*11 were detected: *11A (-344T, -40T, 445A, 459A, 640G, and 1095A) and *11C (-344T, -40T, 459A, 640G, and 1095A). The allele frequency of NAT1*11 was 4.3% in the cases versus 3.9% in the controls. The rare low-active NAT1*14A was overrepresented in the cases (P = 0.026). With regard to the NAT2 genotype, our data showed: (a) a partial linkage of NAT1*10 to NAT2*4; (b) a clear underrepresentation of NAT1*10 genotypes among rapid NAT2 genotypes in the cases studied (odds ratio, 0.39; 95% confidence interval, 0.22–0.68; P = 0.001), and (c) a gene-gene-environment interaction. NAT2*slow/NAT1*4 genotype combinations with a history of occupational exposure were 5.96 (2.96–12.0) times more frequent in cancer cases than in controls without risk occupation (P < 0.0001). Hence, our data suggest that individuals provided with NAT2*4 and NAT1*10 are at a significantly lower risk for bladder cancer, particularly when exposed to environmental risk factors.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
J.-M. Yuan, K. K. Chan, G. A. Coetzee, J.E. Castelao, M. A. Watson, D. A. Bell, R. Wang, and M. C. Yu
Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer
Carcinogenesis, July 1, 2008; 29(7): 1386 - 1393.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
S. Sanderson, G. Salanti, and J. Higgins
Joint Effects of the N-Acetyltransferase 1 and 2 (NAT1 and NAT2) Genes and Smoking on Bladder Carcinogenesis: A Literature-based Systematic HuGE Review and Evidence Synthesis
Am. J. Epidemiol., October 1, 2007; 166(7): 741 - 751.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. Li, L. Jiao, Y. Li, M. A. Doll, D. W. Hein, M. L. Bondy, D. B. Evans, R. A. Wolff, R. Lenzi, P. W. Pisters, et al.
Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer
Carcinogenesis, January 1, 2006; 27(1): 103 - 111.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Gago-Dominguez, D. A. Bell, M. A. Watson, J.-M. Yuan, J.E. Castelao, D. W. Hein, K. K. Chan, G. A. Coetzee, R. K. Ross, and M. C. Yu
Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2
Carcinogenesis, March 1, 2003; 24(3): 483 - 489.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.